[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"energy-expenditure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:energy-expenditure":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,73,104,128,156,193,220,242,275,300,332],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100455859","genesis-genotype-guided---natriuretic-peptides---cardiometabolic-health-study-100455859",false,"NCT05216042","GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study","Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18; an equal number of Males and Females\n* Consent to the collection of genetic material\n* Willing to adhere to the study protocol\n\nExclusion Criteria:\n\n* Age \\\u003C18, at screening.\n* BMI \\>45 kg\u002Fm2.\n* Blood pressure more than 140\u002F90 mmHg.\n* Participants who are taking more than 2 hypertension medications.\n* History of diabetes or fasting plasma glucose \\>126 mg\u002Fdl or HbA1C\\>=6.5% or prior treatment with antidiabetic medication.\n* Have any past or present history of cardiovascular diseases (stroke, seizure, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence);\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Anemia (men, Hct \\\u003C 38%; women, Hct \\\u003C36%)\n* Inability to exercise on a treadmill",true,"ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \\~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have \\~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.",[27,28,29,30,31,32,33],"Cardiovascular Diseases","Natriuretic Peptides","Cardiometabolic Diseases","Energy Expenditure","Glucose Metabolism","Exercise","Obesity",[28,27,31,30,32,33],"RECRUITING","2026-04-03",{"date":38,"type":39},"2026-04-09","ACTUAL",{"date":41,"type":39},"2022-04-01",{"date":43,"type":21},"2027-04-30",{"name":45,"class":46},"University of Alabama at Birmingham","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100627083","effect-of-resistance-exercise-on-energy-balance-and-appetite-regulation-in-males-and-females-100627083","NCT07444021","Effect of Resistance Exercise on Energy Balance and Appetite Regulation in Males and Females","Inclusion Criteria:\n\n* Healthy males and females aged 20-30 years\n* Females with a regular menstrual cycle\n* Stable body weight, defined as no significant change in body weight during the past 6 months\n* Willingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Obesity, defined as:\n* Body mass index (BMI) \\> 30 kg\u002Fm²\n* Body fat percentage \\> 25% in males\n* Body fat percentage \\> 30% in females\n* Hypertension, defined as resting blood pressure \\> 140\u002F90 mmHg\n* History of cardiovascular disease\n* History of cancer\n* History of liver disease\n* History of kidney disease\n* Presence of any medical condition that may interfere with study outcomes","20 Years","30 Years",{"count":57,"type":21},30,[24],"There is growing evidence that males and females may exhibit different acute responses and long-term adaptations to exercise training. Accordingly, contemporary exercise physiology research increasingly recognizes sex as an important biological variable that may influence appetite regulation and energy balance.\n\nThis year's project aims to investigate: (1) appetite regulation and energy balance following acute resistance exercise, and (2) potential sex-based differences in appetite regulation and energy balance in response to resistance exercise.\n\nUnderstanding both the overall effects of resistance exercise and sex-related variability in these responses is important for improving the physiological interpretation of exercise-induced changes in appetite and energy balance. Such knowledge may help to reduce heterogeneity in exercise research findings and support the development of more precise, evidence-based exercise prescriptions that are applicable to both males and females.",[61,30,62,63],"Energy Balance","Males and Females","Resistance Exercise","2026-02-25",{"date":66,"type":39},"2026-03-02",{"date":68,"type":39},"2025-12-01",{"date":70,"type":21},"2026-12-30",{"name":72,"class":46},"National Taiwan Normal University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":80,"minAge":54,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100623994","effects-of-acute-sleep-deprivation-on-health-100623994","NCT07403864","Effects of Acute Sleep Deprivation on Health","Effects of Acute Partial Sleep Deprivation on Metabolic Health and Cognitive Function","Inclusion Criteria:\n\n* Age between 20-45 years.\n* Body Mass Index (BMI) between 18.5-27 kg\u002Fm².\n* No sleep-related medical conditions and good sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≤ 5.\n* Usual bedtime between 22:00-01:00, wake-up time between 06:00-09:00, with an average sleep duration of 7 to 9 hours; chronotype classified as \"definitely not evening type\" (score ≥ 42 on the Morningness-Eveningness Questionnaire), and no changes in sleep patterns over the past 3 months.\n* Without any metabolic or cardiovascular diseases, and not using medications that could affect metabolic responses.\n* No specific dietary habits, such as intermittent fasting or a ketogenic diet.\n* Maintaining a stable weight (no self-reported weight change ± 3 kg) for at least 3 months.\n* Resting blood pressure ≤ 130\u002F80 mmHg.\n* No smoking or excessive alcohol consumption.\n* Not a shift worker.\n* No international travel across time zones has occurred within the past 3 months.\n\nExclusion Criteria:\n\n* Special diets (e.g., intermittent fasting, ketogenic diet)\n* Recent injuries or contraindications to intense exercise.","MALE","45 Years",{"count":83,"type":21},48,[24],"This study will investigate whether various types of regular exercise can provide protective effects against metabolic abnormalities induced by sleep restriction. It will examine responses related to metabolic health, cognitive function, energy expenditure, subjective feelings, and human behaviors, including physical activity and energy intake.",[87,30,88,89],"Glucose Intolerance","Vascular Stiffness","Cognition",[91,92,93,94],"Partial sleep deprivation","Sleep loss","Physical inactivity","Exercise habits","NOT_YET_RECRUITING","2026-02-04",{"date":98,"type":39},"2026-02-11",{"date":100,"type":21},"2026-03-01",{"date":102,"type":21},"2027-03-01",{"name":72,"class":46},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":80,"minAge":54,"maxAge":81,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":47},"100590068","effects-of-intermittent-running-on-metabolic-health-100590068","NCT06962605","Effects of Intermittent Running on Metabolic Health","Acute Effects of Intermittent vs. Continuous Running Exercise on Physiological and Metabolic Responses","Inclusion Criteria:\n\n* Healthy recreationally active men\n* BMI between 18.5-27 kg\u002Fm2\n* Aged between 20 to 45 years\n* Regular exercise (3 times per week and longer than 3 months) with cardio exercise longer than 30 minutes at least once a week\n* Weight stable for more than 3 months (no change in weight +\u002F- 3%)\n* Non-shift workers and sleep at least 6.5-9 hours for the past 3 months\n* Non-smoker\n\nExclusion Criteria:\n\n* having any cardiovascular, metabolic or pulmonary disease (angina pectoris or uncontrolled arrhythmias)\n* suffering from infectious contagious diseases,\n* using medications that could affect metabolic responses (including anti-inflammatory medications)\n* smoking\n* heavy alcohol intake (more than 4 drinks on any day or more than 14 drinks a week).\n* undergoing special diets (e.g., intermittent fasting and\u002For ketogenic diets)",{"count":112,"type":21},16,[24],"The purpose of this study is to investigate the suitability of intermittent exercise of long and short intervals at lower intensities than HIIE on energy expenditure during and post-exercise compared to MICE, as well as determine whether similar or greater effects can be achieved for glycemic control in recreationally active adults.",[116,30],"Metabolic Regulation",[118,119],"Intermittent running","Energy expenditure","2026-01-23",{"date":122,"type":39},"2026-01-26",{"date":124,"type":39},"2025-06-21",{"date":126,"type":21},"2026-04-30",{"name":72,"class":46},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":47},"100540754","phase-2-vital-impact-improving-cardiometabolic-health-in-black-individuals-through-therapeutic-augmentation-of-cyclic-guanosine-mono-phosphate-signaling-pathway-100540754","NCT06320951","VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway","Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway","VITAL-IMPACT","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18 years of age\n* Self-identified race\u002Fethnicity as African-American or Black\n* BMI ≥ 30 kg\u002Fm2\n* HOMA-IR ≥ 2.5\n* Blood pressure: 120-160\u002F80-100 mmHg (untreated or 1 week of washout in those treated with up to two classes of antihypertensives)\n* Willing to adhere to study protocol\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)\n* Have any past or present history of cardiovascular diseases (stroke, myocardial infarction, heart failure, transient ischemic attack, angina, seizure or cardiac arrhythmia)\n* BP more than 160\u002F100 mmHg or those treated with three or more classes of antihypertensives\n* BMI \\>45 kg\u002Fm2\n* History of diabetes or fasting plasma glucose \\>=126 mg\u002FdL or HbA1C\\>=6.5% or prior treatment with antidiabetics\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin-creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Significant psychiatric illness (assessed using validated MINI questionnaire)\n* Anemia (men, Hb\\\u003C13 g\u002FdL; women, Hb \\\u003C12 g\u002FdL)\n* Inability to exercise on a treadmill","80 Years",{"count":20,"type":21},[139],"PHASE2","This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.",[27,142,143,144,30,33],"Insulin Sensitivity\u002FResistance","Metabolic Disease","Metabolism",[30,146,147,148],"Insulin Sensitivity","African Americans","Cyclic Guanosine Monophosphate","2026-01-21",{"date":120,"type":39},{"date":152,"type":21},"2026-12-01",{"date":154,"type":21},"2029-04-30",{"name":45,"class":46},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":16,"sex":17,"minAge":164,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":47},"100600324","studying-phenotypic-risks-for-obesity-and-underlying-traits-in-young-infants-100600324","NCT07096011","Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants","Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants: A Pilot Study","SPROUT","Inclusion Criteria:\n\n* Aged 2 weeks to less than 17 weeks at screening\n* Being fed human milk as a primary source of food\n* Be willing to consume one meal of infant formula\n* Be willing to complete a DXA measurement\n\nExclusion Criteria:\n\n* Unable to complete the screening visit and two clinic visits within 14 days\n* Born with health conditions that would render procedures unsafe\n* Born earlier than 35 days and 0 weeks gestation\n* Eating supplemental foods\n* Physician diagnosed feeding difficulties that may require a special type of nipple for bottle feeding","2 Weeks","16 Weeks",{"count":167,"type":21},40,"OBSERVATIONAL","The purpose of this research study is to understand how infants metabolize different meals and to develop clinical tools which identify infants as having two different phenotypes. The phenotypes are the 1) metabolic \"thriftiness\" and 2) the metabolic flexibility.",[171,144,30,172,173,174],"Infant Body Composition and Metabolism","Infant Formula","Human Milk, Breast Milk","Metabolic Flexibility",[176,177,178,179,180,181,182,183],"infant","metabolism","energy expenditure","infant formula","breast milk","human milk","thrifty phenotype","metabolic flexibility","2025-08-21",{"date":186,"type":39},"2025-08-22",{"date":188,"type":39},"2025-07-28",{"date":190,"type":21},"2027-05",{"name":192,"class":46},"Pennington Biomedical Research Center",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":16,"sex":80,"minAge":18,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":47},"100549323","sources-and-mechanisms-of-energy-compensation-100549323","NCT06432517","Sources and Mechanisms of Energy Compensation","Identification of the Sources and Mechanisms of Energy Compensation in Humans","Inclusion Criteria:\n\n* Healthy adults (men)\n* 18-40 years old\n* BMI (body mass index)≥18.5 kg\u002Fm2\n\nExclusion Criteria:\n\n* Those who have undergone surgery in the past 6 months.\n* People are requiring long-term medication.\n* People have metabolic diseases, like diabetes, hypoglycemia, gout, osteoporosis, et al.\n* People have digestive diseases, like gastric ulcer, pancreatitis, Intestinal obstruction, et al.\n* People have sports injury, like fracture, Joint injury, et al.\n* Those who have recently lost weight for various medical reasons (e.g. cancer, etc.).\n* People are losing weight by tablets.\n* People are suffering from infectious diseases (e.g. HIV, etc.)\n* People have blood phobia, pathological hypo or hyper tension.\n* People with impaired glucose tolerance.\n* Those who are afflicted with claustrophobia.","40 Years",{"count":202,"type":21},81,[24],"Excess energy, obesity and obesity-related diseases are important global health issues. Although it is known that obesity is an issue of energy balance, the components of energy expenditure seem to be inter-related in complex non-additive ways. The aim of this study is to explore the downstream impacts of exercise on short term changes in both expenditure and energy intake. The primary question the investigators are asking is whether moderate to high intensity exercise influences the basal energy expenditure and\u002For energy intake\u002Fmacronutrient preference in young adult males? (A similar study will be performed on females in a different registration). The investigators will use a specially designed feeding table to measure energy intake and macronutrient intake, which is easy to quantify intake compensation. Basal metabolism will be measured by hood indirect calorimetry. The investigators will explore the factors that influence the level of compensation in expenditure and intake, in particular body composition. Participants will be asked to come to the lab after 10 hours fast for body composition tests including Dual Energy X-ray Absorptiometry(DXA), Magnetic Resonance Image(MRI) and Bioelectrical Impedance Analysis(BIA). They will then be asked (not) to do 30 minutes of moderate-to-vigorous exercise after an energy-limiting breakfast, during which metabolic rate levels and changes in dietary composition will be recorded by gas exchange and standardized buffet. In addition, participants' subjective hunger and preferences will also be recorded by questionnaires. Venous blood will be collected to measure metabolic and hormone factors, blood glucose will be measured by Continuous Blood Glucose Monitor (CGM).",[30,32,206,207],"Energy Intake","Food Preferences",[209,210,207],"Energy compensation","Energy balance","2025-08-11",{"date":213,"type":39},"2025-08-15",{"date":215,"type":39},"2024-05-20",{"date":217,"type":21},"2025-12-30",{"name":219,"class":46},"Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":47},"100366758","phase-2-nautical-effect-of-natriuretic-peptide-augmentation-on-cardiometabolic-health-in-black-individuals-100366758","NCT04055428","NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals","The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals (NAUTICAL)","Inclusion Criteria:\n\n* Adults: Age more than or equal to 18 years of age\n* Self-identified race\u002Fethnicity as African-American or Black\n* Blood pressure: 120-160\u002F80-100 mmHg\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence)\n* Have any past or present history of cardiovascular diseases (stroke, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)\n* BP more than 160\u002F100 mmHg\n* BMI \\>45 kg\u002Fm2\n* History of diabetes or fasting plasma glucose \\>=126 mg\u002FdL or HbA1C\\>=6.5%\n* History of angioedema\n* Current or past (\\\u003C12 months) history of smoking\n* Estimated GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m2; albumin-creatinine ratio ≥30 mg\u002Fg\n* Hepatic Transaminase (AST and ALT) levels \\>3x the upper limit of normal\n* Significant psychiatric illness or seizure disorder\n* More than 2 Alcoholic drinks daily\n* Anemia (men, Hct \\\u003C 38%, Hb\\\u003C13 g\u002FdL; women, Hct \\\u003C36%, Hb \\\u003C12 g\u002FdL)\n* Inability to exercise on a treadmill",{"count":20,"type":21},[139],"Black individuals are more likely to have decreased insulin sensitivity which results in a high risk for the development of cardiometabolic disease. The reasons for this are incompletely understood. Natriuretic peptides (NPs) are hormones produced by the heart that play a role in regulating the metabolic health of an individual. Low circulating level of NPs is an important contributor to increased risk for diabetes. The NP levels are relatively lower among Black individuals thus affecting their metabolic health and putting them at a higher risk for diabetes. This study aims to test the hypothesis that by augmenting NP levels using sacubitril\u002Fvalsartan, among Black Individuals one can improve their metabolic health (as measured by insulin sensitivity \\& energy expenditure) and help establish the role of NPs in the underlying mechanism behind increased risk for cardiometabolic disease in these population.",[231,27,142,143,28,144,30],"Diabetes Mellitus",[28,233,146,30],"Diabetes","2025-07-01",{"date":236,"type":39},"2025-07-03",{"date":238,"type":39},"2020-08-15",{"date":240,"type":21},"2027-05-31",{"name":45,"class":46},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":263,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":47},"100589205","the-impact-of-daily-intake-of-short-chain-fatty-acids-on-cardiometabolic-risk-factors-in-individuals-at-risk-for-metabolic-syndrome-100589205","NCT06951386","The Impact of Daily Intake of Short-chain Fatty Acids on Cardiometabolic Risk Factors in Individuals at Risk for Metabolic Syndrome","The Impact of 12 Weeks Intervention With Plant-based Oat Drink Rich in Short-chain Fatty Acids on Postprandial Lipidemia in Individuals at Risk for Metabolic Syndrome","12OATS","Inclusion Criteria:\n\n* male and female participants\n* central obesity ( BMI ≥ 25 kg\u002Fm² or waist circumference ≥ 80 cm for women\u002F ≥ 94 cm for men)\n* One additional risk factor for metabolic syndrome:\n\n  1. Insulin resistance (HOMA-IR ≥ 1.7 or fasting glucose ≥ 100 mg\u002Fdl)\n  2. Triglyceride concentration ≥ 150 mg\u002Fdl\n  3. HDL-cholesterol \\\u003C 40 mg\u002Fdl for women\u002F \\\u003C 50 mg\u002Fdl for men\n  4. Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg\n* knowledge of English\n\nExclusion Criteria:\n\n* gastrointestinal disorders such as IBD, IBS, celiac disease, chronic constipation, chronic diarrhoea\n* history of abdominal surgery, except for appendectomy\n* Use of antihypertensive, cholesterol lowering, glucose-regulating drugs and corticosteroids\n* Use of antibiotics 3 months prior to the start or during the study\n* Use of probiotics and prebiotics 2 weeks prior to the start of the study\u002F during the study\n* Being on weight loss, gluten-free, lactose-free or vegan diet\n* Pregnancy, lactation or wish to become pregnant\n* Previous or current substance\u002F alcohol dependence or abuse\n* Hyper- or hypothyroidism\n* Allergy or intolerance to oat milk","65 Years",{"count":252,"type":21},50,[24],"During this study, the effect of short-chain fatty acids on blood lipaedemia, glycemia, anthropometrics, blood pressure and energy expenditure will be investigated.",[30,256,257,258,259,260,261,262],"Metabolic Syndrome","Anthropometry","Body Composition","Glycemia","Lipaemia","Metabolomics","Blood Pressure",[264,265],"short-chain fatty acids","cardiometabolic health","2025-04-30",{"date":268,"type":39},"2025-05-04",{"date":270,"type":39},"2025-02-11",{"date":272,"type":21},"2026-02-28",{"name":274,"class":46},"KU Leuven",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":283,"minAge":18,"maxAge":4,"enrollmentInfo":284,"targetDuration":286,"studyType":168,"phases":4,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":47},"100585709","resting-energy-expenditure-in-postmenopausal-women-100585709","NCT06905886","Resting Energy Expenditure in Postmenopausal Women","Impact of Menopausal Hormone Therapy on Resting Energy Expenditure in Postmenopausal Women","MenoBOLISM","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Healthy postmenopausal woman\n* Indication for MHT (e.g. climacteric syndrome, osteoporosis, etc.)\n* Body Mass Index (BMI) 18.5 - 29.9 kg\u002Fm2\n* Non smoker\n* Willingness to maintain unchanged dietary habits and the type and frequency of sports activities throughout the entire 6-week study period. I.e. no dietary changes\u002Frestrictions, start of a special exercise program or start of any weight-loss measures are planned during the study period.\n\nExclusion Criteria:\n\n* Pregnancy or Lactation\n* Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)\n* Systemic hormone therapy or hormonal contraception (estrogens, progestogens, androgens) during the study and within 12 weeks prior to study entry\n* Phytotherapeutics for therapy of climacteric syndrome during the study and within 12 weeks prior to study entry\n* Use of psychotropic drugs and other drugs that have an influence on resting energy expenditure during the study and within 12 weeks prior to study entry\n* Substance abuse (e.g. nicotine, alcohol, drugs)\n* Use of appetite suppressants\n* Hypersensitivity or allergy to class of drugs or to any ingredients of the used IMPs (Oestrogel® and Utrogestan®)\n* Contraindication for estradiol or progesterone medication according to swissmedicinfo.ch: Neoplasia of the breast or other sexual organ; Benign or malignant liver tumors; Acute or chronic liver disease; Cholestatic jaundice; Porphyria; Arterial or venous thromboembolic events; Abnormal genital bleeding of unknown cause\n* Use of medication with active ingredients that interact with the metabolization of estradiol or progesterone. For each medication a drug interaction check will be performed: Lexicomp® Drug Interactions, UpToDate®\n* Known or suspected non-compliance due to inability to follow the procedures of the study (e.g. illiteracy, language problems, psychological disorders, dementia, etc.)","FEMALE",{"count":285,"type":21},37,"6 Weeks","Obesity and its associated comorbidities are rising at an alarming rate, particularly among postmenopausal women. Menopause, characterized by a decline in estradiol and progesterone levels, is often accompanied by weight gain. Fear of this weight gain is a major reason why many women hesitate to initiate or continue menopausal hormone therapy (MHT), with discontinuation often occurring within the first few months. However, scientific evidence on whether MHT influences weight gain remains inconclusive. A Cochrane Review found no significant effect of estrogen or combined estrogen-progestogen therapy on menopause-related weight gain, suggesting that aging and lifestyle changes play a more prominent role.\n\nWhile the effects of estrogen on energy intake have been well-documented, data on its impact on energy expenditure-particularly resting energy expenditure (REE), the largest component of total energy expenditure-are scarce. Several studies suggest that sex hormones may influence REE, as observed in premenopausal women, where REE increases during the luteal phase when estradiol and progesterone levels are high. However, findings on this topic remain inconsistent, and it is unclear whether estrogen or progesterone plays the primary role. Research on the effects of exogenous hormone administration, such as MHT, on REE is extremely limited, with existing studies producing mixed results. Additionally, the potential influence of progestogens on REE has been largely overlooked. Given that a low REE is a strong predictor of weight gain and obesity, understanding the effects of MHT on REE is crucial.\n\nThis observational clinical trial aims to investigate the precise effect of MHT (estradiol + progesterone) on REE in postmenopausal women with an indication for MHT. Secondary objectives include examining MHT's impact on energy intake, physical activity energy expenditure, performance capacity, body composition, core body temperature, serum hormone profiles (luteinizing hormone, follicle-stimulating hormone, estradiol, progesterone), glucose metabolism, fasting blood lipid levels, and miRNA expression (miR-370 and miR-29b, which are involved in lipid and glucose metabolism). Additionally, the study will assess various aspects of subjective well-being and quality of life.\n\nBy addressing the current gaps in scientific knowledge, this study seeks to provide robust evidence on the role of MHT in energy metabolism, potentially reshaping perspectives on its risks and benefits in postmenopausal women.",[289,30,290],"Postmenopause","Hormone Replacement Therapy","2025-03-31",{"date":293,"type":39},"2025-04-02",{"date":295,"type":21},"2025-08",{"date":297,"type":21},"2027-02",{"name":299,"class":46},"Insel Gruppe AG, University Hospital Bern",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":16,"sex":17,"minAge":308,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":22,"phases":312,"briefSummary":313,"conditions":314,"keywords":317,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":47},"100547952","the-energyco-study-100547952","NCT06414668","The ENERGYCO Study","ENERGY Expenditure of COmmuting to School","ENERGYCO","Inclusion Criteria:\n\n1. the school has a specific space for parking bicycles and allows for their parking\n2. the school does not have a specific school bus route\n3. the school has at least two lines per class\n4. at least eight students from the school will agree to participate in the study (i.e., presenting a signed parental consent).","12 Years","17 Years",{"count":311,"type":21},300,[24],"The aims of this school-based cycling intervention called \"ENERGY Commuting to school\" (ENERGYCO) will be divided into two phases: Phase I will aim: 1) to design, test, and validate predictive equations for the objective quantification of the energy expenditure related to different modes of commuting to school (i.e., walking, cycling, motorized-vehicle); and 2) to quantify the energy expenditure of each mode of commuting to school using indirect calorimetry in adolescents; and Phase II will aim to evaluate the effect of a school-based cycling intervention on different health-related outcomes, such as energy expenditure, resting metabolic rate, basal metabolism, physical activity levels, body composition, muscle strength, cardiorespiratory fitness, blood pressure, physical literacy, motor competence, and psychosocial outcomes on Spanish adolescents.",[30,315,316,258],"Physical Activity","Behavior",[318,119,319,320,321,322],"Resting metabolic rate","Physical activity","Body composition","Cycling","School","2024-12-03",{"date":325,"type":39},"2024-12-05",{"date":327,"type":39},"2023-02-01",{"date":329,"type":21},"2025-06-30",{"name":331,"class":46},"Universidad de Granada",{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":338,"eligibilityCriteria":339,"healthyVolunteers":16,"sex":80,"minAge":200,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":22,"phases":343,"briefSummary":344,"conditions":345,"keywords":348,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":47},"100552793","the-energy-cost-of-1-hour-football-training-100552793","NCT06477705","The Energy Cost of 1-Hour Football Training","Energy Expenditure Induced by Football Training in Overweight Middle-aged Males","FAM","Inclusion Criteria:\n\n* Free of musculoskeletal injuries\n* No use of ergogenic supplements or medication\n* Free of chronic diseases\n* age of 40-60 years\n* BMI\\>25\n* Metabolic syndrome\n\nExclusion Criteria:\n\n* Musculoskeletal injury\n* Use of alcohol, caffeine and any type of ergogenic supplements or medication during the course of the study","60 Years",{"count":342,"type":21},20,[24],"This study aims at investigating the energy expenditure following a single Football trainning session in middle aged males. The participants will perform a soccer training session \\[A single training session including 60 minutes of warm up, soccer technical exercises and small-sided game\\] and a cotrol trial (No intervention included, only daily measurements) in randomized, repeated measures, crossover design.",[30,258,346,347],"Resting Metabolic Rate","Overweight and Obesity",[349,30,350,351,256],"Football training","Oxygen consumption","Blood lactate","2024-06-28",{"date":354,"type":39},"2024-07-01",{"date":356,"type":39},"2024-06-23",{"date":358,"type":21},"2024-07-08",{"name":360,"class":46},"University of Thessaly"]